Hyfe has announced results from a proof-of-concept clinical trial validating the effectiveness of its digital chronic cough platform.

The study demonstrated that Hyfe’s digital Behavioral Cough Suppression Therapy (BCST) reduced cough frequency by more than 40% in patients suffering from refractory and unexplained chronic cough (RCC/UCC). According to the study, 80% of participants experienced a clinically meaningful improvement in quality of life, highlighting the potential of digital therapeutics to deliver non-drug treatment options for a condition that affects an estimated 10% of adults worldwide.

The US-based company’s digital approach works by embedding BCST protocols directly into its CoughPro wellness monitoring app. This innovation enables patients to access guided behavioral therapy from their smartphones while leveraging Hyfe’s AI-driven cough monitoring to measure progress in real time.

Study Design and Key Findings

The single-cohort proof-of-concept study evaluated ten participants with refractory chronic cough over a four-week treatment period. Participants used the Hyfe digital therapeutic to monitor cough activity and complete structured BCST modules.

On average, participants experienced a 41.8% reduction in cough frequency and a 41.5% decrease in cough bouts. Those with more severe baseline symptoms, defined as coughing more than ten times per hour, achieved even greater improvements, with reductions of 43.9% in cough frequency and 44.2% in cough bouts.

Additionally, 80% of participants reported a clinically meaningful improvement in quality of life, as measured by the Leicester Cough Questionnaire (LCQ). By transforming BCST into a digital format, Hyfe bridges the gap between clinical research and real-world accessibility. The app provides education about cough hypersensitivity, interactive training modules for suppression techniques, and continuous AI-based monitoring to ensure measurable progress.

Dr. Peter Small, Hyfe’s Chief Medical Officer, emphasized the importance of these findings: “These results mark a pivotal step toward expanding access to proven cough therapies through digital innovation. By digitizing behavioral cough suppression, we can extend effective treatment to millions globally who currently lack access.”

Hyfe boasts that its technology, validated across more than 50 clinical studies, uses patented machine-learning algorithms capable of accurately detecting and quantifying coughs. This capability empowers both clinicians and patients to track outcomes objectively and adjust care strategies accordingly.

The study strengthens the case for wider adoption of digital therapeutics in managing chronic cough and other respiratory conditions. With Kyorin Pharmaceuticalalready launching this treatment in Japan, Hyfe anticipates further international partnerships to expand access to more patients worldwide.